<DOC>
	<DOCNO>NCT00402363</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Omacor ( omega-3-acid ethyl ester ) patient recurrent , symptomatic atrial fibrillation .</brief_summary>
	<brief_title>Evaluation Efficacy Safety Lovaza ( Omega-3-Acid Ethyl Esters ) Recurrent , Symptomatic Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Men woman age 18 year old History symptomatic atrial fibrillation ( either paroxysmal persistent ) Provide write informed consent authorization protect health information disclosure Permanent ( chronic ) atrial fibrillation Antiarrhythmic drug therapy stop Use amiodarone prior 6 month History unsuccessful cardioversion History certain cardiovascular condition cardiac surgery within prior 6 month History stroke within prior 6 month Implanted cardiodefibrillator Certain circulatory , thyroid , pulmonary , liver , kidney , musculoskeletal metabolic condition , cancer ( except nonmelanoma skin cancer ) Poorly control diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Lovaza</keyword>
	<keyword>Omega-3 fatty acid</keyword>
	<keyword>Omacor</keyword>
	<keyword>Paroxysmal atrial fibrillation</keyword>
</DOC>